Anamorelin hydrochloride is under clinical development by Helsinn Healthcare and currently in Phase II for Fatigue. According to GlobalData, Phase II drugs for Fatigue does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Anamorelin hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anamorelin hydrochloride overview
Anamorelin hydrochloride (RC-1291, ONO-7643) is under development for the treatment of cancer cachexia/anorexia in non-small cell lung cancer (NSCLC) patients and cancer-related fatigue. It is a new molecular entity which is formulated as a tablet and is administered orally. The drug candidate acts by targeting the ghrelin receptor.
See Also:
It was also under development for the treatment of cancer cachexia/anorexia in EU.
Helsinn Healthcare overview
Helsinn Healthcare, a subsidiary of Helsinn Holding SA, is a cancer care company that offers oncology products and therapies. The company includes research and development, drug discovery and manufacturing of formulations of drug products in therapeutic areas of pain and inflammation, cancer supportive care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, Klean-Prep and laxaclear. The company also offers integrated early and late-stage licensing programs for its own drug discovery and development programs. It operates research and development facilities in Dublin, Ireland, Biasca, Switzerland and supplies products across the US, Monaco, Japan and China. Helsinn Healthcare is headquartered in Lugano, Switzerland.
For a complete picture of Anamorelin hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.